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Atrial Fibrillation and Torsade
Persistent Atrial Fibrillation Is Associated
With Reduced Risk of Torsades de Pointes
in Patients With Drug-Induced Long QT Syndrome
Dawood Darbar, MD, FACC,* John Kimbrough, MD, PHD,* Asif Jawaid,* Robert McCray, MD,†
Marylyn D. Ritchie, PHD,‡ Dan M. Roden, MD, FACC*†
Nashville, Tennessee
Objectives The goal of this study was to identify markers of torsades de pointes (TdP) in patients with drug-associated long
QT syndrome (LQTS).
Background Drug-induced LQTS includes individuals developing marked prolongation of ventricular repolarization on expo-
sure to an offending drug. Under these conditions, TdP develops in some but not all patients.
Methods This was a case-control study of 123 adults with drug-associated LQTS. Patients were divided into LQTS only
(LQTS; n  40, QT 500 ms on drug) and LQTS  TdP (TdP; n  83).
Results Baseline QT intervals were similar in the 2 groups (381  38 ms [LQTS] vs. 388  43 ms [TdP]). Clinical vari-
ables associated with risk of TdP included hypokalemia and female gender; by contrast, persistent atrial fibrilla-
tion (AF) at the time of drug discontinuation for QT prolongation was protective despite similar heart rates in AF
and sinus rhythm (n  20, 71  13 beats/min vs. 69  13 beats/min). Electrocardiographic variables that sig-
nificantly increased the risk for TdP included absolute and rate-corrected QT intervals (QTc) on drug therapy, the
magnitude of QT and QTc interval prolongation, and the change in Tpeak to Tend (Tp–Te), a relatively new index
of transmural dispersion of repolarization and potential arrhythmogenicity. Multivariable logistic regression anal-
ysis revealed that only gender was predictive for TdP, whereas persistent AF at the time of drug discontinuation
for QT prolongation (odds ratio 0.14, 95% confidence interval 0.03 to 0.63, p  0.01) was negatively associated
with the arrhythmia.
Conclusions This study strongly suggests that despite ongoing rate irregularity, AF reduces the likelihood of developing TdP
after the administration of drugs that prolong cardiac repolarization. (J Am Coll Cardiol 2008;51:836–42)
© 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.09.066d
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Qarked prolongation of ventricular action potential dura-
ion, shown on the surface electrocardiogram (ECG) as QT
rolongation, can cause the life-threatening arrhythmia
orsades de pointes (TdP) (1,2). Administration of QT-
rolonging antiarrhythmic drugs is the most common cause
f the drug-associated (acquired) long QT syndrome
LQTS), although other drugs, notably antihistamines,
ntipsychotics, and gastrointestinal prokinetic agents, have
een implicated (3–5). In the past decade, the single most
ommon cause of the withdrawal or restriction of the use of
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007, accepted September 19, 2007.rugs that have already been marketed has been the pro-
ongation of the QT interval associated with TdP. Although
uidelines aimed at predicting whether a new drug carries
his risk have been developed, current predictors of this
erious side effect are imperfect, both for individuals and for
opulations of patients exposed to a given drug (6,7).
Risk factors for acquired LQTS have been identified and
nclude high drug doses, bradycardia, and hypokalemia (8).
owever, predicting development of TdP, particularly in
he absence of high doses or plasma concentrations, can be
roblematic (9,10). Although it may be possible to predict
hat a given drug may carry some risk, neither accurate
ssessment nor quantification of the risk has so far been
ossible. In fact some drugs that significantly prolong the
T interval are only rarely associated with TdP; this may beecause of their limited effect on transmural dispersion of
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February 26, 2008:836–42 Drug-Induced LQTS and TdPepolarization (TDR) (11). One reason that predicting TdP
emains challenging relates to the impracticality of perform-
ng large-scale, prospective, placebo-controlled studies that
ay delineate individual characteristics predisposing to
rug-induced TdP. The goals of this study, therefore, were
o evaluate clinical and electrocardiographic characteristics
redictive of development of TdP in a cohort of patients
ith drug-associated LQTS.
ethods
atient ascertainment. This was a retrospective case-
ontrol study of patients enrolled in the Vanderbilt Ac-
uired LQTS Registry. Inclusion criteria included age 18
ears, documented QT prolongation (500 ms), and/or
dP after exposure to a known QT-prolonging drug or drug
ombination with a baseline QT interval that was normal
QT 440 ms). Torsades de points was defined in terms of
ypical ECG features, including QT prolongation or defor-
ity, pause-dependent onset, and sustained polymorphic
entricular tachycardia (faster than 150 beats/min and
asting 10 beats) with QRS complexes of changing am-
litude that twist around the isoelectric line. Often however,
his twisting morphology may not be apparent when only
hort bursts occur; consequently, episodes of ventricular
achycardia that were 10 beats were not considered
iagnostic for TdP. Over a 15-year period, 146 patients
ere enrolled in the registry. Of these, 93 patients devel-
ped TdP and 50 had QT prolongation alone. However, for
hese analyses patients (n  8) without baseline ECGs
efore initiation of the drug therapy or those in whom an
CG was not obtained within 24 h of either discontinuing
rug therapy because of QT interval prolongation or an
pisode of TdP were excluded. In addition, in 15 patients
elemetry strips were of insufficient quality to measure the
T intervals and the data from these patients were also
xcluded from the analyses. For Vanderbilt patients, in-
ormed consent approved by the institutional review board
as obtained. For non-Vanderbilt patients, local Human
ubjects approval was obtained.
Atrial fibrillation (AF) was defined as the replacement of
inus P waves by rapid oscillations or fibrillatory waves that
aried in size, shape, and timing and were associated with an
rregular ventricular response when the atrioventricular con-
uction was intact. Documentation of AF on an ECG, rhythm
trip, event monitor, or Holter monitor was required.
Arterial hypertension was defined by a history of hyper-
ension and patients taking an antihypertensive agent.
riteria for coronary artery disease (CAD) included a
istory of myocardial infarction or typical angina, previous
ypass surgery, or angioplasty or drug treatment. Congestive
eart failure (CHF) was defined by a history of CHF or
rug treatment for heart failure. Left ventricular hypertro-
hy was electrocardiographically defined by either the Cor-
ell voltage (SV3 RaVL)2.8 mV for men and2.0 mV cor women or Sokolow-Lyon
oltage amplitude (SV1  RV5
r RV6) 3.5 mV.
T analysis. The ECGs were
nalyzed using a semiautomated
igitizing program by an experi-
nced observer blinded to all
linical details. The QT interval
as measured from the onset of
he QRS interval to the end of
he T-wave in all of the leads
here the end of the T-wave
ould be clearly defined. The
ongest QT interval in any of these leads was used as the
easured QT interval. The mean of 3 consecutive QT
ntervals were measured not only in sinus rhythm (SR), but
lso when the patient was in AF. The mean QT was then
orrected for the heart rate (QTc) with the preceding time
uration between 6 consecutive R waves of the ECG (RR
nterval) and the Bazett formula (QTc  QT/RR1/2) (12).
owever, formulas that normalize QT-interval measure-
ents to heart rate may be problematic in acquired LQTS;
dditionally, formulas designed for SR may be inappropriate
or irregular rhythms such as AF, therefore changes in
bsolute QT durations are also reported (13). A new
easure of arrhythmogenicity that has been proposed is the
peak–Tend (Tp–Te) interval, which is the interval from the
ummit of the T wave to the end of the QT interval
14 –16). Whenever double T waves (also known as
otched, humped, or pathological U waves) were present,
he first and second components of the T-wave were defined
s T1 and T2. The QT interval was then measured from the
nset of the QRS interval to the end of T2, whereas Tp–Te
as measured from the summit of T1 to the end of T2 (17).
hysiological U waves, defined as U waves that are smaller
han the T-wave and are completely separated from it by an
soelectric segment, were not counted as part of any of the
T interval. Although baseline 12-lead ECGs were avail-
ble in all patients, 25 (20%) patients only had single-lead
elemetry strips at the time of drug discontinuation because
f QT prolongation or TdP. In these patients, the same lead
as used for QT interval measurement at baseline and after
nitiation of drug therapy.
Intraobserver variability was examined by randomly se-
ecting 50 ECGs to be reanalyzed by the same observer; the
oefficient of variation (standard deviation/mean  100) for
T and Tp–Te measurements were 3% to 7% and 2% to 4%,
espectively. To examine for interobserver variability, inde-
endent duplicate determination were made by a second
linded observer; the coefficient of variation between pa-
ients was 7% to 9% and 6% to 8% for QT and Tp–Te
valuations, respectively.
tatistical analysis. Continuous variables are expressed as
ean  standard deviation, and their distributions were
nalyzed using the Shapiro-Wilks test of normality. A
Abbreviations
and Acronyms
AF  atrial fibrillation
ECG  electrocardiogram
LQTS  long QT syndrome
SR  sinus rhythm
TdP  torsades de pointes
TDR  transmural
dispersion of repolarization
Tp–Te  Tpeak to Tendomparison between the groups was performed with Stu-
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Drug-Induced LQTS and TdP February 26, 2008:836–42ent t test or the nonparametric Wilcoxon rank-sum test, as
ppropriate. Categorical variables, expressed as numbers and
ercentages, were compared with the Fisher exact test. The
elationship between clinical and ECG variables and devel-
pment of TdP was further assessed with univariate and
ultivariable logistic regression analyses, and results are
eported as odds ratios (ORs) with 95% confidence intervals
CIs). All tests of significance were 2-tailed, and a p value of
0.05 was considered to indicate statistical significance.
esults
ne hundred twenty-three unrelated patients whose ECG
howed QT prolongation500 ms and/or TdP during drug
hallenge, and whose ECG recovered to normal after the
ffending drug was stopped, constituted the study cohort.
hese 123 patients included 83 patients (TdP group) who
ere diagnosed with drug-associated TdP. The remaining
0 patients (LQTS group) who developed QT interval
rolongation without TdP constituted the control group.
here were no episodes of polymorphic ventricular tachy-
ardia 10 beats in the study cohort. Cases are included
ere both from Vanderbilt University Medical Center (n 
04) and elsewhere (n  19). The clinical history was
btained by review of patient medical records.
linical characteristics. The clinical characteristics of the
groups of patients are shown in Table 1. The 2 groups
ere matched for age, the prevalence of CAD, hyperten-
ion, and ECG-defined left ventricular hypertrophy. How-
ver, the proportion of women was significantly higher in
he TdP group.
Table 2 shows the drugs that patients were taking at the
ime of QT interval prolongation or development of TdP.
ine of the drugs were conventional antiarrhythmic drugs,
nd 11 were noncardiovascular agents. A 12-lead ECG
howing QT interval prolongation (700 ms) from a 36-year-
atient Characteristics
Table 1 Patient Characteristics
TdP Group
(n  83)
LQTS Group
(n  40)
Age (yrs) 59 13 59 15
Female (%) 56 (67) 14 (42)*
Hypertension (%) 54 (65) 22 (55)
CHF (%) 34 (41) 10 (25)
Coronary artery disease (%) 30 (36) 16 (40)
Left ventricular hypertrophy (%) 15 (18) 8 (20)
Cardiomyopathy (%) 12 (14) 4 (10)
Diuretics 21 (25) 8 (20)
Serum potassium (mEq/l) 3.9 0.6
(n  79)
4.1 0.5
(n  38)
Serum magnesium (mEq/l) 1.9 0.5
(n  45)
1.9 0.2
(n  20)
Hypokalemia, 3.5 mEq/l (%) 53 (64) 3 (8)†
p  0.01 versus TdP group. †p  0.001.
CHF  congestive heart failure; LQTS  long QT syndrome; TdP  torsades de pointes.ld man treated with quinidine for AF is shown in Figure 1. An contrast, Figure 2 (top panel) shows an ECG from a
atient started on sotalol during AF, showing minimal
hange in QT intervals despite frequent short-long-short
ycles. After direct current cardioversion, the QT interval
as increased dramatically to over 640 ms (middle panel)
nd an episode of TdP is triggered (bottom panel).
F in cohort. Baseline heart rate in AF was comparable in
he TdP group (80  16 beats/min) and LQTS group (78
14 beats/min, p  0.05), as was the heart rate in the
on-AF groups (TdP 62  12 beats/min vs. LQTS 66 
0 beats/min, p 0.05). The QT and QTc in the AF group
ere similar to those patients who were in SR before
nitiation of a QT-prolonging drug (QT: AF 384  40 ms
s. SR 390  34 ms; QTc: AF 410  38 ms vs. SR 420 
6 ms, p 0.05). At baseline, 29 (35%) patients in the TdP
roup were in AF compared with 17 (42%) patients in the
QTS group. The AF was of the persistent type in the
ajority of these patients (Table 3). However, AF was
resent at the time of TdP in only 5 of 83 (6%) patients
ersus 15 of 40 (38%) in the LQTS group. In the remaining
8 patients in whom TdP occurred during SR, it developed
n 17 (22%) patients after termination of AF by antiarrhyth-
ic drugs. Eight patients were treated with intravenous
ntiarrhythmic drugs, and TdP occurred after restoration of
R in 7 patients. In patients who were initiated on oral
ntiarrhythmic drugs for restoration or maintenance of SR,
dP developed an average of 2.8  1.2 days after initiation
f the therapy. Furthermore, there seemed to be no differ-
nce in the culprit drugs between the TdP and LQTS
roups. Fifty patients were initiated on class I antiarrhyth-
ic drugs, and TdP developed in 27 (54%) compared with
3 (44%) patients, in whom LQTS only developed. There
as a similar finding with class III antiarrhythmic drugs
ulprit Drugs
Table 2 Culprit Drugs
Drug Type No. of Patients
Antiarrhythmic drugs
Quinidine 35
Sotalol 28
Dofetilide 9
Procainamide 8
Disopyramide 7
Amiodarone 3
Others/combined AADs 11
Nonantiarrhythmic drugs
Trimethoprim-sulfamethoxazole 4
Phenothiazines 3
Haloperidol 3
Fluconazole/itraconazole 3
Cisapride 2
Pentamidine 2
Lithium 1
Terfenadine 1
Clarithromycin 1
Others/combined drugs 2ADs  antiarrhythmic drugs.
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February 26, 2008:836–42 Drug-Induced LQTS and TdPTdP 49% vs. LQTS 51%, p  0.05). It is not possible to
valuate whether there were differences in nonantiarrhyth-
ic culprit drugs because there were only a limited number
f patients in the 2 groups.
T interval analyses. A comparison between the TdP and
QTS groups was performed with the Student t test for the
ajority of the ECG variables except when comparing the
hange in QT (QT), QTc, on drug Tp–Te, and
Figure 1 A 12-Lead ECG Taken in a Patient 2 Days After Comm
The longest QT interval was measured at 700 ms in lead III. AF  atrial fibrillation
Figure 2 ECG From a Patient Started on Sotalol
(Top) During AF, there is irregularity of ventricular response creating frequent shor
current cardioversion, the QT interval has increased dramatically to 640 ms and (bTp–Te when it was more appropriate to utilize the
ilcoxon rank sum test. Heart rates at baseline and on drug
herapy were similar, as were QT intervals in the 2 groups
Table 4). However, absolute, Bazett-corrected and QT
ere significantly longer in the TdP group compared with
ontrol patients. In addition, TDR measured as the absolute
nd Tp–Te was also significantly longer in patients who
xperienced TdP.
ng Quinidine for AF
 electrocardiogram.
hort cycles, but there is minimal change in QT intervals. (Middle) After direct
) an episode of torsades de pointes is triggered. Abbreviations as in Figure 1.enci
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Drug-Induced LQTS and TdP February 26, 2008:836–42The relationship between clinical and ECG variables and
evelopment of TdP was further assessed with univariable
nd multivariable logistic regression analyses. On univariate
nalysis, the following variables were found to be associated
ith the development of TdP: gender (OR 3.40, 95% CI
.23 to 5.19, p  0.0001); on drug QT (OR 1.01, 95% CI
.01 to 1.02, p  0.001); on drug QTc (OR 1.01, 95% CI
.00 to 1.01, p  0.02); QT (OR 1.01, 95% CI 1.01 to
.02, p  0.001); QTc (OR 1.01, 95% CI 1.00 to 1.01, p
 0.01); Tp–Te (OR 1.02, 95% CI 1.00 to 1.04, p 
.02); hypokalemia (OR 4.98, 95% CI 1.38 to 17.93, p 
.01) and AF at time of TdP (OR 0.08, 95% CI 0.02 to
.26, p  0.0001). On multivariable logistic regression
nalysis (Table 5), lack of persistent AF was the strongest
redictor of development of TdP. However, female gender
as also associated with increased risk of TdP, and there
as a trend toward significance for hypokalemia.
iscussion
n this study, we showed for the first time that patients
xposed to QT prolonging drugs are less likely to develop
dP when the underlying rhythm is persistent AF as
ompared with SR. However, female gender was identified
s a significant risk factor for development of TdP.
haracteristics of Patientsith AF in he Study Cohort
Table 3 Characteristics of PatientsWith AF in the Study Cohort
TdP Group
(n  83)
LQTS Group
(n  40)
AF at baseline (%) 29 (35%) 17 (42%)
Type of AF (paroxysmal/persistent) 11/18 7/10
Oral AADs (%) 58 (70%) 30 (75%)
Intravenous AADs (%) 8 (10%) 6 (15%)
Persistent AF at time of TdP or drug
discontinuation (%)
5 (6%) 15 (37%)*
DC cardioversion (%) 18 (22%) 10 (25%)
p  0.0001 versus TdP group.
AF   atrial fibrillation; other abbreviations as in Tables 1 and 2.
lectrocardiographic Variablesn Patients With TdP and LQTS
Table 4 Electrocardiographic Variablesin Patients With TdP and LQTS
TdP Group
(n  83)
LQTS Group
(n  40)
Baseline HR (beats/min) 66 14 68 12
On drug HR (beats/min) 71 13 69 13
Baseline QT (ms) 381 38 388 43
Baseline QTc (ms) 408 31 416 36
On drug QT (ms) 598 76 547 57†
On drug QTc (ms) 615 70 584 48*
QT (ms) 217 79 159 61†
QTc (ms) 207 81 168 61*
Baseline Tp–Te (ms) 94 21 94 16
On drug Tp–Te (ms) 152 39 133 30*
Tp–Te (ms) 58 34 39 30†
p  0.05. †p  0.001 compared with TdP group.d
HR  heart rate; Tp–Te  T-wave peak to T-wave end;   change; other abbreviations as in
able 1.Although TdP can occur in many settings (such as heart
lock, as originally described), it is usually seen in patients
ith one of the congenital LQTS or in association with
rug therapy. In recent years, a growing list of cardiac and
oncardiac drugs (many of which are listed in Table 2) with
ction potential prolonging properties, and a discernible
rolongation of the QT interval on the surface ECG has
een reported (8). This effect is frequently seen in clinical
ractice (e.g., in approximately 2% of patients receiving
uinidine) and results from a drug-mediated action on
pecific cardiac ion channel (IKr), which leads to a net
mbalance between inward and outward ion currents during
epolarization.
Multiple risk factors for drug-induced TdP have been
elineated. However, estimating an individual patient’s risk
s difficult. Often, a combination of individual disease
actors (e.g., hypokalemia, underlying heart disease), envi-
onmental factors, and specific triggers are present, which in
ssociation reduce repolarization reserve and thus markedly
rolong the QT interval to a critical threshold level (18).
lthough hypokalemia and female gender have previously
een identified as independent predictors of TdP (19), AF
t the time of QT interval prolongation has not previously
een shown to reduce the risk of developing TdP.
easurement of QT intervals during AF. Rate correc-
ion of the QT interval using standard Bazett (12) and
ridericia (20) formulae can introduce significant errors in
ssessment of drug effects on the QT interval (13). In a
ariable rhythm such as AF with constantly changing RR
ntervals, this is even more pronounced, because the QT
nterval adapts to changes in heart rate and simply averaging
ultiple QT intervals will not provide adequate assessment
f QT during AF. The most reliable method for rate
orrection is one that is based on the QT–RR relationship
21). Recently, a method of measuring the QT interval that
s rate independent has been proposed, and one study
howed that cardioversion of AF acutely increases the QT
nterval and the steepness of the QT/RR slope (22). Thus,
n the LQTS group, in which AF is more prevalent, the
orrection formulae would predict QTc to be greater than
QT. In contrast, in the TdP group, in which SR is more
revalent, the Bazett formula would predict the opposite.
onsequently, the application of correction formulae that
ormalize QT interval measurements to heart rate and were
ultivariate Logistic Regression Analysis
Table 5 Multivariate Logistic Regression Analysis
Multivariate Logistic
Regression Analysis
OR 95% CI p Value
Hypokalemia (K 3.5 mEq/l) 4.88 0.95–24.97 0.06
Gender (female) 2.40 1.11–5.19 0.03
Persistent AF at time of event
(TdP or drug discontinuation)
0.14 0.03–0.63 0.01
I  confidence interval; OR  odds ratio; TdP  torsades de pointes; other abbreviations as in
able 3.esigned for SR may be inappropriate for irregular rhythms
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February 26, 2008:836–42 Drug-Induced LQTS and TdPuch as AF. Our data presented in Table 4 clearly show that
hanges in absolute QT durations may be more valid under
hese circumstances (13).
F and TdP. In this study we show that persistent AF
educed the likelihood of patients developing TdP when
dministered QT-prolonging drugs. This is surprising given
he frequent short-long-short cycles in AF, but is in accord
ith previous reports indicating heightened risk after con-
ersion of AF (23). There are a number of lines of evidence
hat suggest dysregulation of the QT interval in AF. One
iece of evidence comes from studies of QT prolonging
ntiarrhythmic drugs, whose major contemporary indication
s prevention and conversion of AF. Virtually all of these
rugs block the rapid component of the cardiac-delayed
ectifier (IKr) as a major mechanism of action, and marked
T prolongation and pause-dependent TdP are the major
lass toxicities. Clinical anecdotes have long suggested that
dP, when it occurs in this setting, develops after conver-
ion of rhythm to SR and rarely when the underlying
hythm remains AF (23,24). To test these anecdotes, we
ave previously infused the potent IKr blocker dofetilide in
patients before and immediately after cardioversion of AF,
nd showed that although there was little QT prolongation
uring AF, some patients displayed striking QT prolonga-
ion (and 1 had TdP) in the post-cardioversion challenge
25). Additionally, a recent study not only confirmed that
T intervals are longer for any given RR interval after
estoration of SR, but also that the slope of the QT–RR
elationship was found to be unexpectedly flat in AF when
ompared with SR (22). Steepening of the QT–RR rela-
ionship after cardioversion of AF is consistent with the
ypothesis that susceptibility to TdP is low during AF
despite frequent short-long-short cycles) and elevated after
ardioversion.
p–Te and TdP. Recent experimental studies involving
he canine arterially perfused wedge preparation have sup-
orted the idea that the substrate for TdP develops as a
onsequence of the amplification of electrical heterogene-
ties intrinsic to the ventricular myocardium (26–28). These
eterogeneities exist because of differences in the time
ourse of repolarization of the 3 predominant cell types that
ake up the ventricular myocardium, giving rise to trans-
ural voltage gradients and a TDR responsible for the
lectrocardiographic T-wave. In these studies, the duration
f the second part (T2) of the T-wave is thought to represent
measure of TDR (i.e., a long Tp–Te interval is thought to
ndicate augmented TDR). The arrhythmogenic role of in-
reased TDR under long QT conditions as well as in the
rugada syndrome has been reported (14–16). In this study,
e found that prolongation of Tp–Te and Tp–Te correlated
ith development of TdP and that this may be useful for
redicting TdP in patients with drug-induced LQTS.
otential mechanism. Atrial fibrillation is associated with
ignificant remodeling that includes alterations in L-type
alcium current, inward rectifier current, transient outward
urrent, and ultrarapid delayed rectifier current (among pther changes) (29). The magnitude of these changes is
ufficient to alter responses to antiarrhythmic drugs. How-
ver, molecular changes in the left ventricle secondary to AF
re less well established. Nonetheless, there are echocardio-
raphic data that link AF, atrial remodeling, reverse remod-
ling, and changes in left ventricular systolic function (30).
lthough the precise mechanism by which AF reduces
usceptibility to TdP is unknown, AF-associated electro-
hysiological and cellular remodeling may perhaps be asso-
iated with preservation of TDR that correlates with re-
uced susceptibility to the development of TdP among
atients with acquired LQTS. Additionally, a recent study
hat modeled LQTS by infusing veratridine into Langen-
orff preparations of rabbit hearts was able to show that the
isk of developing TdP could be significantly decreased
hrough preventing prolongation in TDR by verapamil ad-
inistration (31). Their finding is in agreement with our
urrent study in which TDR (Tp–Te ) was significantly
horter in acquired LQTS patients who did not develop TdP.
tudy limitations. Although this was a retrospective anal-
sis, the data for this study were obtained from one of the
argest single-center acquired LQTS registries. However, to
ully evaluate the role of AF and risk of TdP requires a
uch larger multicenter clinical study. Another limitation
elates to the fewer number of subjects in the LQTS group.
his was probably related to discontinuation of QT pro-
onging drugs, and it is possible that continued administra-
ion of QT prolonging drugs in this group could have
esulted in further prolongation of myocardial repolarization
nd TdP. The time course of QT interval changes may be
n important determinant of development of TdP, and in
ur study an accurate assessment of this variable in patients
xposed to nonantiarrhythmic drugs was not available, nor
ere there comprehensive data on how QT intervals
hanged if conversion from AF to SR occurred. The
vailability of only telemetry strips, albeit performed around
he time of drug discontinuation or an episode of TdP, is
nother potential limitation of the study. Although potas-
ium levels and diuretic regimes in patients with heart
ailure were known for many patients in this cohort,
agnesium levels were not, and hence reliable determina-
ion of this factor as a predictor of TdP was limited.
There are no established methods for evaluating QT
ntervals in patients with AF. We and others have used QT
veraging over multiple heart rates and then rate-corrected
T (25,32). Although averaging at least 10 beats for QT
easurement would have provided more representative
ean QT values, we were limited to averaging 3 consecutive
eats because prolonged ECG recordings were not available
or most patients in this study.
In conclusion, this study has shown that patients in
ersistent AF are at reduced risk of developing TdP after
xposure to QT-prolonging drugs. Reduced risk of devel-
ping TdP was also strongly associated with preserved
DR. Additionally, female gender was also an independent
redictor of developing TdP.
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